Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Taheri, Hoda, Malek, Mojtaba, Ismail-Beigi, Faramarz, Zamani, Farhad, Sohrabi, Masoudreza, Reza babaei, Mohammad, Khamseh, Mohammad E. · 2020 · Advances in Therapy

Abstract

INTRODUCTION: Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a high percentage of individuals is available. Beneficial effects of sodium-glucose co-transporter 2 inhibitors on fatty liver have been investigated in people with type 2 diabetes (T2DM). The aim of this study was to explore the effect of empagliflozin on liver steatosis and fibrosis in patients with NAFLD without T2DM. METHODS: In this prospective randomized, double-blind, placebo-controlled clinical trial, participants with NAFLD were randomized to empagliflozin (10 mg/day) (n = 43) or placebo (n = 47) for 24 weeks. Hepatic steatosis and fibrosis were assessed using transient elastography to measure the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). The primary outcome was the change in CAP score at 24 weeks. RESULTS: There was significant decrease in CAP score in both groups but no significant difference was observed between the two groups (P = 0.396). LSM was significantly decreased in the empagliflozin-treated group (6.03 ± 1.40 to 5.33 ± 1.08 kPa; P = 0.001), while no change was found in the placebo group. In subgroups analysis of patients with significant steatosis at baseline (CAP ≥ 302 dB/m), steatosis significantly improved in the empagliflozin group (37.2% vs. 17%; P = 0.035). There was a significant decrease in the grade of liver fat on visual analysis of ultrasound images, AST, ALT, and fasting insulin levels in the empagliflozin group, while no changes were observed in the placebo group. CONCLUSIONS: Empagliflozin improves liver steatosis and, more importantly, measures of liver fibrosis in patients with NAFLD without T2DM. TRIAL REGISTRATION: ClinicalTrials.gov identifier, IRCT20190122042450N1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-020-01498-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 32

  1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95. · DOI · Paper page
  2. Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int. 2009;29(2):159–63. · DOI
  3. Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–24. · DOI · Paper page
  4. Jung C-H, Mok J-O. The effects of hypoglycemic agents on non-alcoholic fatty liver disease: focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J Obes Metab Syndr. 2019;28(1):18. · DOI
  5. Razavi-Nematollahi L, Ismail-Beigi F. Adverse effects of glycemia-lowering medications in type 2 diabetes. Curr Diab Rep. 2019;19(11):132. · DOI
  6. Gharaibeh NE, Rahhal M-N, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1001. · DOI
  7. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30. · DOI · Paper page
  8. Sasso M, Beaugrand M, De Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. · DOI · Paper page
  9. Yen Y-H, Chen J-B, Cheng B-C, et al. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: a prospective cohort study. PLoS One. 2017;12(4):e0176027. · DOI
  10. Bouchi R, Nakano Y, Ohara N, et al. Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15(1):64. · DOI
  11. Hsing JC, Nguyen MH, Yang B, et al. Associations between body fat, muscle mass, and nonalcoholic fatty liver disease: a population-based study. Hepatol Commun. 2019;3(8):1061–72. · DOI
  12. Banini BA, Sanyal AJ. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, natural history, diagnosis, and current treatment options. Clin Med Insights Ther. 2016;8:75–84.
  13. The Oxford Center for Diabetes, Endocrinology and Metabolism. HOMA2 Calculator. Oxford: Diabetes Trial Unit; 2009.
  14. Wanner M, Probst-Hensch N, Kriemler S, Meier F, Autenrieth C, Martin BW. Validation of the long international physical activity questionnaire: influence of age and language region. Prevent Med Rep. 2016;3:250–6. · DOI
  15. Lee Y-H, Kim JH, Kim SR, et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J Korean Med Sci. 2017;32(1):60–9. · DOI
  16. Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92. · DOI · Paper page
  17. Khan RS, Newsome PN. Fat and fibrosis: does empagliflozin impair the progression of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus? Dig Dis Sci. 2020;65:342–4. · DOI
  18. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40. · DOI · Paper page
  19. Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20(2):438–42. · DOI · Paper page
  20. Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr J. 2017;64(3):363–7. · DOI
  21. Seko Y, Sumida Y, Sasaki K, et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53(1):140–51. · DOI
  22. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8. · DOI · Paper page
  23. Roulot D, Roudot-Thoraval F, Nkontchou G, et al. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. Liver Int. 2017;37(12):1897–906. · DOI
  24. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(S1):S99–S112. · DOI · Paper page
  25. Leiter L, Forst T, Polidori D, Balis D, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):25–322. · DOI
  26. Hawley SA, Ford RJ, Smith BK, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94. · DOI · Paper page
  27. Kurinami N, Sugiyama S, Yoshida A, et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;142:254–63. · DOI
  28. Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–72. · DOI · Paper page
  29. Katsuyama H, Hakoshima M, Iijima T, Adachi H, Yanai H. Effects of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes: a chart-based analysis. J Endocrinol Metab. 2020;10(1):1–7. · DOI
  30. Ohta A, Kato H, Ishii S, et al. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. Expert Opin Pharmacother. 2017;18(14):1433–8. · DOI
  31. Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128(4):371–80. · DOI
  32. Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars). 2018;13(1):402–9. · DOI

Cited by

See all 188

Metadata

Authors
Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E.
Venue
Advances in Therapy
Published
2020-09-25
Volume
37
Issue
11
Pages
4697-4708
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W3088344065
Cited by
188
References
7
FWCI
12.90
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1007/s12325-020-01498-5
The paper
Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E. (2020). Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Advances in Therapy. https://doi.org/10.1007/s12325-020-01498-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.